Prevalence of ESBLs genes among multidrug-resistant isolates of pseudomonas aeruginosa isolated from patients in Tehran

Microbial Drug Resistance

Volumn 15, Issue 1, 2009, Pages 37-39

  Shahcheraghi, Freshteh ^a   Nikbin, Vajiheh Sadat ^a   Feizabadi, Mohammad Mehdi ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; DISK DIFFUSION; IRAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DNA PRIMERS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS; HUMANS; IRAN; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

PSEUDOMONAS AERUGINOSA;

EID: 66749157997     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2009.0880     Document Type: Article

References (18)

1. Al-Jasser, A.M. 2006. Extended-spectrum beta-lactamases (ESBLs). A global problem. Kuwait. Med. J. Rev. 38:171-185.
2. Biedenbach, D.J., G.J. Moet, and R.N. Jones. 2004. Occurrence and antimicrobial resistance pattern among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Micro-biol. Infect. Dis. 50:59-69.
3. Claeys, G., G. Verschraegen, T. de Baere, and M. Va-neechoutte. 2000. PER-1 β-lactamase-producing Pseudomo-nas aeruginosa in an intensive care unit. J. Antimicrob. Chemother. 45:919-931.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. NCCLS documents M100-S12. CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard document M7-A7. CLSI, Wayne, PA.
6. Endimiani, A., F. Luzzaro, B. Pini, G. Amicosante, G.M. Rossolini, and A.Q. Toniolo. 2006. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of PER-1 extended-spectrum b-lactamase, BMC. Infect. Dis. 6:52-61.
7. Girlich, D., L. Poirel, A. Leelaporn, A. Karim, C. Tribud-dharat, M. Fennewald, and P. Nordmann. 2001. Molecular epidemiology of the integron-located VEB-1 extended-spectrum beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J. Clin. Microbiol. 39:175-182.
8. Haley, R.W., D.H. Culver, J.W. White, W.M. Morgan, and T.G. Emori. 1985. The nationwide nosocomial infection rate: a new need for vital statistics. Am. J. Epidemiol. 121:159- 161.
9. Lee, S., Y.J. Park, M. Kim, H.K. Lee, K. Han, C.S. Kang, and M.W. Kang. 2005. Prevalence of Ambler class A and D β-lactamases among clinical isolates of Pseudomonas aerugi-nosa in Korea. J. Antimicrob. Chemother. 56:122-127.
10. Navon-Venezia, S., R. Ben-Ami, and Y. Carmeli. 2005. Update on Pseudomonas aeruginosa and Acinetobacter bau-mannii infections in the healthcare setting. Curr. Opin. Infect. Dis. 18:306-313.
11. Nordmann, P., E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia. 1993. Characterization of a novel β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:962-969.
12. Pickett, M.J., and J.R. Greenwood. 1986. Identification of oxidase-positive, glucose-negative, motile species of non-fermentative bacilli. J. Clin. Microbiol. 23:920-923.
13. Rossolini, G.M., and E. Mantegoli. 2005. Treatment and control of severe infections caused by multiresistant Pseu-domonas aeruginosa. Clin. Microbiol. Infect. 11:17-32.
14. Vahaboglu, H., R. Oztürk, G. Aygün, F. Coşkunkan, A. Yaman, A. Kaygusuz, H. Leblebicioglu, I. Balik, K. Aydin, and M. Otkun. 1997. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acine-tobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multi-center study. Antimicrob. Agents Che-mother. 41:2265-2269.
15. Vahaboglu, H., S. Saribas, H. Akbal, R. Ozturk, and A. Yucel. 1998. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acineto-bacter spp. J. Antimicrob. Chemother. 42:269-270.
16. Vincent, J.L., D.J. Bihari, P.M. Suter, H.A. Bruining, J. White, M.H. Nicolas-Chanoin, M. Wolff, R.C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care unit in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. JAMA 274:639-644.
17. Weldhagen, G.F., L. Poirel, and P. Nordmann. 2003. Ambler class A extended-spectrum beta-lactamases in Pseudo-monas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 47:2385-2392.
18. Wisplinghoff, H., T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.